Pure Global

Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.[PedPQP (BA/FE)] - Trial NCT05930782

Access comprehensive clinical trial information for NCT05930782 through Pure Global AI's free database. This Phase 1 trial is sponsored by Medicines for Malaria Venture and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05930782
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05930782
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.[PedPQP (BA/FE)]
A Randomized, Open Label, Two-part, Parallel-group, Phase I Study to Evaluate the Pharmacokinetics of Piperaquine Oral Dispersible Granules Formulation Compared to Piperaquine Hard Tablets Administered as a Single Dose in Fasting Condition (Part 1) and of Piperaquine Oral Dispersible Granules Formulation Administered as Single Dose in Various Fed States (Part 2) in Healthy Adult Participants

Study Focus

Malaria

Piperaquine Phosphate

Interventional

drug

Sponsor & Location

Medicines for Malaria Venture

Timeline & Enrollment

Phase 1

Jul 01, 2023

Dec 01, 2023

60 participants

Primary Outcome

Relative bioavailability (Frel) of the Maximum Observed Plasma Concentration (Cmax) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel Cmax).,Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to 72h hours (AUC0-72h) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-72h).,Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to the last quantifiable concentration (AUC0-t) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-t).,Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to 168 hours (AUC0-168h) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-168h.,Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero extrapolated to infinity (AUC0-โˆž) of the PQP dispersible granule compared to the PQP hard tablet in the fasted state (Frel AUC0-โˆž).

Summary

This trial aims to characterise the pharmacokinetic (PK) profile and estimate drug exposure
 of a single oral dose of piperaquine (PQP) in a dispersible granule formulation compared to
 the PQP hard tablet formulation in the fasted state (Part 1), to advise the selection of dose
 when the PQP granule formulation is administered in a fed state in healthy adult
 participants. Part 2 will assess the effect on different types of meal composition on the PK
 of a single dose of PQP granule formulation in healthy adult participants.

ICD-10 Classifications

Unspecified malaria
Plasmodium malariae malaria
Plasmodium falciparum malaria
Other parasitologically confirmed malaria
Plasmodium ovale malaria

Data Source

ClinicalTrials.gov

NCT05930782

Non-Device Trial